{
    "id": 17890,
    "fullName": "RSPO2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "RSPO2 over exp indicates an over expression of the Rspo2 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 340419,
        "geneSymbol": "RSPO2",
        "terms": [
            "RSPO2",
            "CRISTIN2",
            "HHRRD",
            "TETAMS2"
        ]
    },
    "variant": "over exp",
    "createDate": "02/12/2016",
    "updateDate": "04/19/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4471,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, advanced solid tumor cells overexpressing Rspo2 in culture and in xenograft models demonstrated inhibition of beta-catenin activity and suppression of tumor growth when treated with RSPO2 specific antibodies suggesting RSPO2 may be a promising therapeutic target (PMID: 26719531).",
            "molecularProfile": {
                "id": 18199,
                "profileName": "RSPO2 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4577,
                    "pubMedId": 26719531,
                    "title": "Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates \u03b2-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26719531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11814,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived xenograft (PDX) model of triple-receptor negative breast cancer overexpressing RSPO2 demonstrated inhibition of tumor growth when treated with IWR-1 (PMID: 28472820).",
            "molecularProfile": {
                "id": 18199,
                "profileName": "RSPO2 over exp"
            },
            "therapy": {
                "id": 2455,
                "therapyName": "IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9858,
                    "pubMedId": 28472820,
                    "title": "Clinical value of R-spondins in triple-negative and metaplastic breast cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28472820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18199,
            "profileName": "RSPO2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}